College of Life Science and Bio-engineering, Beijing University of Technology, Beijing, 100124, China.
College of Life Science and Bio-engineering, Beijing University of Technology, Beijing, 100124, China.
Drug Discov Today. 2017 Nov;22(11):1680-1685. doi: 10.1016/j.drudis.2017.08.010. Epub 2017 Sep 4.
Machine intelligence, which is normally presented as artificial intelligence, refers to the intelligence exhibited by computers. In the history of rational drug discovery, various machine intelligence approaches have been applied to guide traditional experiments, which are expensive and time-consuming. Over the past several decades, machine-learning tools, such as quantitative structure-activity relationship (QSAR) modeling, were developed that can identify potential biological active molecules from millions of candidate compounds quickly and cheaply. However, when drug discovery moved into the era of 'big' data, machine learning approaches evolved into deep learning approaches, which are a more powerful and efficient way to deal with the massive amounts of data generated from modern drug discovery approaches. Here, we summarize the history of machine learning and provide insight into recently developed deep learning approaches and their applications in rational drug discovery. We suggest that this evolution of machine intelligence now provides a guide for early-stage drug design and discovery in the current big data era.
机器智能,通常被表述为人工智能,是指计算机所展现出的智能。在合理药物发现的历史中,各种机器智能方法已被应用于指导传统实验,这些实验既昂贵又耗时。在过去几十年中,开发了机器学习工具,如定量构效关系 (QSAR) 建模,可快速廉价地从数百万候选化合物中识别出潜在的生物活性分子。然而,当药物发现进入“大数据”时代时,机器学习方法演变为深度学习方法,这是处理现代药物发现方法所产生的大量数据的更强大、更有效的方法。在这里,我们总结了机器学习的历史,并深入探讨了最近开发的深度学习方法及其在合理药物发现中的应用。我们认为,机器智能的这种发展为当前大数据时代的早期药物设计和发现提供了指导。